LipiFlow® Treatment

Ocular surface rehabilitation is critical before patients undergo cataract and refractive surgery, and Meibomian glands play a major role in ocular surface health. Because so many patients present with dry eye disease (DED) and Meibomian gland dysfunction (MGD), physicians must have safe, effective, and reliable treatment plans in place. The LipiFlow® System is one of them.

The LipiFlow® System is intended for the application of localized heat and pressure therapy for adult patients who have chronic cystic conditions of the eyelids, including Meibomian Gland Dysfunction (MGD). This in office procedure allows physicians to treat your MGD without visiting any surgical centers or other type of facilities.

  • FDA-cleared device provides inner and outer lid therapy.

  • After initial anesthetic drops, no drugs required for LipiFlow treatment.

  • Efficient, in-office treatment.

  • Long-lasting results – many can see the continued benefit up to 12 months.

  • No pain and/or no discomfort reported for the vast majority of patients.

  • 400,000 treatments worldwide – and growing.

The LipiFlow® System:

What To Expect During The Treatment

The proven LipiFlow® treatment is a simple 12-minute treatment completed in the office. LipiFlow® Activators are single-use sterile devices that safely and comfortably deliver a combination of heat to the inner lids and simultaneous therapeutic massage to the outer lids, removing blockages from the Meibomian glands. Activators are inserted after anesthetic eye drops were instilled.

As a result of removing gland obstructions, your glands are then able to produce the oils essential in protecting your eyes from progressive MGD.

What To Expect After Treatment

Results with LipiFlow® can be experienced 6-8 after treatment and may vary depending on the level of severity of MGD. Because LipiFlow® treats MDG, Dry Eye Disease symptoms are not expected to fully resolve with LipiFlow®. Dry Eye Disease is a multifactorial condition and may require additional treatment.

CONTRAINDICATIONS

Do not use the LipiFlow® System in patients with the following conditions. Use of the device in patients with these conditions may cause injury. Safety and effectiveness of the device have not been studied in patients with these conditions.

  • Ocular surgery within prior 3 months, including intraocular, oculo-plastic, corneal or refractive surgery procedure

  • Ocular injury within prior 3 months

  • Ocular herpes of eye or eyelid within prior 3 months

  • Active ocular infection

  • Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months

  • Eyelid abnormalities that affect lid function

  • Ocular surface abnormality that may compromise corneal integrity

ADVERSE EFFECTS

Potential adverse effects that may occur as a result of the procedure include, but are not limited to, the onset or increase in:

  • Eyelid/eye pain requiring discontinuation of the treatment procedure;

  • Eyelid irritation or inflammation;

  • Ocular surface irritation or inflammation; and

  • Ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light).

Potential serious adverse events (defined as permanent impairment or damage to a body structure or function or necessitates medical or surgical intervention to preclude permanent impairment or damage to a body structure or function) that are not anticipated because of the device mitigations to prevent occurrence include:

  • Thermal injury to the eyelid or eye, including conjunctiva, cornea or lens;

  • Physical pressure-induced injury to the eyelid; and

  • Ocular surface (corneal) infection.